If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. Lund, Sweden, 4 March 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been […]
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of Transplantation and to be presented as a poster at the Cutting Edge of Transplantation (CEoT) Summit, Scottsdale, Arizona, 26–28 February 2026 Regulatory clearance granted by both UK MHRA and […]
Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results. Read more…
Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]
Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen’s 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will […]
